<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946853</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB00060626</org_study_id>
    <nct_id>NCT02946853</nct_id>
  </id_info>
  <brief_title>Junctional AV Ablation in CRT-D: JAVA-CRT</brief_title>
  <official_title>Junctional AV Ablation in CRT-D Patients With Atrial Fibrillation (JAVA-CRT Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac resynchronization therapy (CRT) is a demonstrably effective device intervention for
      patients with heart failure with reduced ejection fraction and specific indication. However,
      many patients with heart failure (HF) are unable to maintain sinus rhythm and approximately
      30-36% of CRT patients are in atrial fibrillation (AF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate if patients with AF indicated for CRT will have
      significant reduction in left ventricular end-systolic volume when randomized to
      atrioventricular junction (AVJ) ablation. In this study, subjects will be randomized to
      receive CRT-D or CRT-D with AVJ ablation. Randomization will be stratified by enrolling
      center (1:1 ratio).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with reduction ≥ 15% in left ventricular end-systolic volume (LVESV)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with improvement in left ventricular ejection fraction (EF)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with improvement in left ventricular end-diastolic volume (LVEDV)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with heart failure hospitalizations</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with implantable cardioverter-defibrillator delivered inappropriate therapy</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with implantable cardioverter-defibrillator delivered appropriate therapy for ventricular tachycardia (VT) or ventricular fibrillation (VF)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of biventricular pacing</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Episodes of ventricular fibrillation following AV junctional ablation as detected on ICD</measure>
    <time_frame>Baseline to one month</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Systolic Heart Failure</condition>
  <condition>Atrial Fibrillation (Permanent)</condition>
  <arm_group>
    <arm_group_label>CRT-D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized at enrollment. Patients in this arm of the study will receive cardiac resynchronization therapy with defibrillator (CRT-D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRT-D and AVJ Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm of the study will receive CRT-D and undergo atrioventricular junctional (AVJ) ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrioventricular junctional (AVJ) ablation</intervention_name>
    <description>RF energy delivery to AV node to create complete AV block</description>
    <arm_group_label>CRT-D and AVJ Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac resynchronization therapy - defibrillator</intervention_name>
    <description>Insertion of device capable of providing biventricular pacing and cardiac defibrillation</description>
    <arm_group_label>CRT-D</arm_group_label>
    <arm_group_label>CRT-D and AVJ Ablation</arm_group_label>
    <other_name>CRT-D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Optimal pharmacologic therapy is defined by published guidelines from the American
             Heart Association and the American College of Cardiology

          -  Initial implantation of CRT-D

          -  Ischemic or nonischemic cardiomyopathy

          -  LVEF ≤ 35%

          -  NYHA class II-IV (ambulatory)

          -  QRS ≥ 120 ms for LBBB and ≥ 150 ms for non-LBBB patients

          -  Continuous AF &gt; 6 months when no further efforts to restore sinus rhythm are feasible
             or pursued

        Exclusion Criteria:

          -  Ventricular rate &gt; 110 bpm at rest despite maximal medical therapy

          -  Ventricular rate &lt; 50 bpm at rest

          -  Heart block/symptomatic bradycardia that necessitates permanent pacing

          -  Acute coronary syndrome or coronary artery bypass surgery within 12 weeks

          -  Severe aortic or mitral valvular heart disease

          -  Prior surgical or percutaneous AF ablation procedure

          -  Prior AVJ ablation

          -  Any medical condition likely to limit survival to &lt; 1 year

          -  Patients with ACC/AHA Stage D refractory Class IV symptoms listed for transplant or
             requiring inotropic support

          -  Contraindication to systematic anticoagulation

          -  Renal failure requiring dialysis

          -  AF due to reversible cause e.g. hyperthyroid state

          -  Pregnancy

          -  Participation in other clinical trials that will affect the objectives of this study

          -  History of non-compliance to medical therapy

          -  Inability or unwillingness to provide informed consent

          -  Patients with short-lived AF or those in sinus rhythm are ineligible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan S Steinberg, MD</last_name>
    <phone>973-436-4155</phone>
    <email>jsteinberg@smgnj.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wojciech Zareba, MD, PhD</last_name>
    <phone>585-275-5391</phone>
    <email>wojciech_zareba@urmc.rochester.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Silver, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Jonathan S. Steinberg</investigator_full_name>
    <investigator_title>Professor of Medicine - Cardiology</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>CRT</keyword>
  <keyword>AV Junction Ablation</keyword>
  <keyword>LVESV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

